HeartSciences Inc.
HSCS · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | -0.02 |
| FCF Yield | -226.01% | -190.20% | -86.20% | -64.62% |
| EV / EBITDA | -0.64 | 0.25 | -1.09 | -2.46 |
| Quality | ||||
| ROIC | -261.80% | -75.49% | -308.13% | -1,385.75% |
| Gross Margin | 56.78% | 67.31% | 45.71% | 45.11% |
| Cash Conversion Ratio | 0.85 | 0.92 | 0.91 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.47% | 8.97% | -41.41% | -39.27% |
| Free Cash Flow Growth | -20.14% | -6.97% | -58.85% | -48.64% |
| Safety | ||||
| Net Debt / EBITDA | -0.23 | 0.78 | 0.02 | -1.18 |
| Interest Coverage | -16.69 | -17.81 | -25.14 | -12.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.01 | 0.00 | 0.01 |
| Cash Conversion Cycle | 64,745.95 | 10,863.93 | 5,873.16 | -894.31 |